ATHE logo

ATHE
Alterity Therapeutics Ltd - ADR

8,857
Mkt Cap
$73.41M
Volume
14,394.00
52W High
$7.00
52W Low
$2.66
PE Ratio
-7.00
ATHE Fundamentals
Price
$4.05
Prev Close
$4.08
Open
$4.11
50D MA
$4.08
Beta
0.90
Avg. Volume
22,520.74
EPS (Annual)
-$0.7383
P/B
2.03
Rev/Employee
$0.00
$17.04
Loading...
Loading...
News
all
press releases
News Placeholder
Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study
(RTTNews) - Alterity Therapeutics Limited (ATHE) on Monday said it received positive feedback from the U.S. Food and Drug Administration following a Type C meeting regarding its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA...
News Placeholder
Alterity Therapeutics Gains FDA Backing For Phase 3 MSA Trial
(RTTNews) - Alterity Therapeutics (ATHE, ATH.AX) announced that it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA...
News Placeholder
Alterity Therapeutics Announces Appointment Of Daniel Claassen As Chief Medical Advisor
(RTTNews) - Alterity Therapeutics Limited (ATHE), Wednesday announced the appointment of Daniel Claassen as Chief Medical Advisor, effective March 2026...
News Placeholder
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available